Prominent examples such as Trastuzumab and Rituximab are routinely used for treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and B-cell malignancies, respectively [2,3]. This evidence concerns the gene ERBB2 and breast carcinoma.